Vetoquinol SA
PAR:VETO

Watchlist Manager
Vetoquinol SA Logo
Vetoquinol SA
PAR:VETO
Watchlist
Price: 76.6 EUR 0.26% Market Closed
Market Cap: 910m EUR
Have any thoughts about
Vetoquinol SA?
Write Note

Vetoquinol SA
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vetoquinol SA
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Vetoquinol SA
PAR:VETO
Total Current Liabilities
€138.8m
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
5%
Sanofi SA
PAR:SAN
Total Current Liabilities
€30B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Total Current Liabilities
€1.7B
CAGR 3-Years
14%
CAGR 5-Years
0%
CAGR 10-Years
17%
Virbac SA
PAR:VIRP
Total Current Liabilities
€530.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Total Current Liabilities
€113.9m
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
Medincell SA
PAR:MEDCL
Total Current Liabilities
€16.5m
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
No Stocks Found

Vetoquinol SA
Glance View

Market Cap
906.5m EUR
Industry
Pharmaceuticals

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

VETO Intrinsic Value
84.87 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vetoquinol SA's Total Current Liabilities?
Total Current Liabilities
138.8m EUR

Based on the financial report for Jun 30, 2024, Vetoquinol SA's Total Current Liabilities amounts to 138.8m EUR.

What is Vetoquinol SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
5%

Over the last year, the Total Current Liabilities growth was 18%. The average annual Total Current Liabilities growth rates for Vetoquinol SA have been -4% over the past three years , 11% over the past five years , and 5% over the past ten years .

Back to Top